alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 726–750 of 1,178 studies published 2024 (page 30 of 48) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Alzheimer and Parkinson diseases, frontotemporal lobar degeneration and amyotrophic lateral sclerosis overlapping neuropathology start in the first two decades of life in pollution exposed urbanites and brain ultrafine particulate matter and industrial nanoparticles, including Fe, Ti, Al, V, Ni, Hg, Co, Cu, Zn, Ag, Pt, Ce, La, Pr and W are key players. Metropolitan Mexico City health crisis is in progress

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in human neuroscience 2024-01-12

The neuropathological hallmarks of Alzheimer's disease (AD), Parkinson's disease (PD), frontotemporal lobar degeneration (FTLD), and amyotrophic lateral sclerosis (ALS) are present in urban children exposed to fine particulate matter (PM2.5), combustion and friction ultrafine PM (UFPM), and industrial nanoparticles (NPs). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Transcranial blood-brain barrier opening in Alzheimer's disease patients using a portable focused ultrasound system with real-time 2-D cavitation mapping

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Theranostics 2024-01-01

BBBO was achieved in 5 out of 6 subjects with an average volume of 983±626 mm 3 following FUS at the right frontal lobe both in white and gray matter regions. 4 key findings →

Design: clinical trial Evidence: low

Full summary, score breakdown and related studies → Original source

Harnessing digital health interventions to bridge the gap in prevention for older adults

✓ Peer-reviewed alzhub usefulness score 45 out of 100. Frontiers in Public Health 2024-01-08

The health issues associated with aging not only have a significant impact on the overall well-being of older individuals but also puts a lot of pressure of the healthcare system (3). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Medical Costs and Caregiver Burden of Delivering Disease-Modifying Alzheimer's Treatments with Different Duration and Route of Administration

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Journal of Prevention of Alzheimer's Disease 2024

Burden of chronic intravenous treatments exceed the gross medical and social care cost savings and value of caregiver benefit. 3 key findings →

Design: modelling Evidence: preliminary

Full summary, score breakdown and related studies → Original source Free full text

MLKL-USP7-UBA52 signaling is indispensable for autophagy in brain through maintaining ubiquitin homeostasis

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Autophagy 2024-09-19

Here, we observed significant compromise in macroautophagy/autophagy in the brains of mlkl knockout (KO) mice, as evidenced by the downregulation of BECN1/Beclin1 and ULK1 (unc-51 like autophagy activating kinase 1). 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Design and Methods of the Early Age-Related Hearing Loss Investigation Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology 2024-06-01

After its completion in 2028, the EARHLI trial should offer evidence on the effect of hearing treatment versus a health education control on cognitive performance, social engagement, and brain organization/connectivity in 55- to 75-year-old community-dwelling adults with early ARHL and amnestic mild cognitive impairment. 2 key findings →

Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Associations of plasma SMOC1 and soluble IL6RA levels with the progression from mild cognitive impairment to dementia

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Brain, behavior, & immunity - health 2024-11-16

Despite the central role attributed to neuroinflammation in the etiology and pathobiology of Alzheimer's disease (AD), the direct link between levels of inflammatory mediators in blood and cerebrospinal fluid (CSF) compartments, as well as their potential implications for AD diagnosis and progression, remains inconclusive. 4 key findings →

Participants: 485 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

FUNCTIONAL OUTCOME IN HOME HEALTH AMONG TRADITIONAL MEDICARE AND MEDICARE ADVANTAGE BENEFICIARIES WITH DEMENTIA

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Innovation in Aging 2024-12-01

This study examines the difference in functional outcomes among Traditional Medicare (TM) and Medicare Advantage (MA) beneficiaries with Alzheimer’s disease and related dementias (ADRD) during a home health admission, which is unknown. 5 key findings →

Design: cohort study Participants: 81,735 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Features of the Physical and Social Neighborhood Environment and Neighborhood-Level Alzheimer’s Disease and Related Dementia in South Carolina

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Environmental Health Perspectives 2024-02-01

; 95% CI: 1.01, 1.04). Neighborhood environment features, such as higher air pollution levels, were associated with higher neighborhood ADRD incidence. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effect of choline alfoscerate in older adult patients with dementia: an observational study from the claims data of national health insurance

✓ Peer-reviewed alzhub usefulness score 44 out of 100. BMC geriatrics 2024-11-16

Choline alfoscerate, a cholinergic precursor with limited evidence of efficacy in dementia management, has been used for various cognitive impairments in Korea. 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source

Expression of regional brain amyloid-β deposition with [18F]Flutemetamol in Centiloid scale -a multi-site study

✓ Peer-reviewed alzhub usefulness score 44 out of 100. Neuroradiology 2024-04-27

14 out of 16 regional conversions from [18F]Flutemetamol SUVr to Centiloid successfully passed the quality control, showing good reliability and relative variance, especially precuneus/posterior cingulate and prefrontal regions with good stability for Centiloid scaling. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Evidence of Pericyte Damage in a Cognitively Normal Cohort: Association With CSF and PET Biomarkers of Alzheimer Disease

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Alzheimer disease and associated disorders 2024-04-01

We demonstrated a moderate positive correlation between PDGFRβ and both total Tau and phosphorylated Tau 181 in cognitively normal individuals. 4 key findings →

Design: cross-sectional Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

γ-Secretase Modulator BPN15606 Reduced Aβ42 and Aβ40 and Countered Alzheimer-Related Pathologies in a Mouse Model of Down Syndrome

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Annals of neurology 2024-05-15

Our findings point to the involvement of increased levels of Aβ42 and/or Aβ40 in contributing to several molecular and cognitive traits associated with DS-AD. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

An Enteric Bacterial Infection Triggers Neuroinflammation and Neurobehavioral Impairment in 3xTg-AD Transgenic Mice

✓ Peer-reviewed alzhub usefulness score 43 out of 100. The Journal of infectious diseases 2024-09-01

Klebsiella pneumoniae is infamous for hospital-acquired infections and sepsis, which have also been linked to Alzheimer disease (AD)-related neuroinflammatory and neurodegenerative impairment. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Neuropsychiatric symptoms profile and markers of Alzheimer disease-type pathology in patients with Lewy body dementias

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Brain research 2024-03-21

We enrolled 69 individuals diagnosed with Lewy body dementia (LBD), comprising both dementia with Lewy bodies (DLB) (n = 36) and Parkinson's disease dementia (PDD) (n = 33). 4 key findings →

Participants: 36 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

New IPECAD Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer's Disease Treatment: Development and Use Cases

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 2024-08-03

Reimbursement decisions for new Alzheimer's disease (AD) treatments are informed by economic evaluations. 3 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

A Data-Driven Approach to Defining Risk-Adjusted Coding Specificity Metrics for a Large U.S. Dementia Patient Cohort

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Healthcare (Basel, Switzerland) 2024-05-24

Medical coding impacts patient care quality, payor reimbursement, and system reliability through the precision of patient information documentation. 3 key findings →

Participants: 487,775 Evidence: low

Full summary, score breakdown and related studies → Original source

P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting p-tau217 with immunotherapy ameliorates murine tauopathy

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Neuron 2024-03-20

Neuronal loss is the central issue in Alzheimer's disease (AD), yet no treatment developed so far can halt AD-associated neurodegeneration. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Evaluating p-tau217 and p-tau231 as Biomarkers for Early Diagnosis and Differentiation of Alzheimer's Disease: A Narrative Review

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Biomedicines 2024-04-03

The escalating prevalence of Alzheimer's disease (AD) highlights the urgent need to develop reliable biomarkers for early diagnosis and intervention. 2 key findings →

Design: narrative review Evidence: low

Full summary, score breakdown and related studies → Original source

The Relationship between p-tau217, p-tau231, and p-tau205 in the Human Brain Is Affected by the Cellular Environment and Alzheimer's Disease Pathology

✓ Peer-reviewed alzhub usefulness score 43 out of 100. Cells 2024-02-11

The levels of p-tau217 and p-tau231 in cerebrospinal fluid (CSF) are associated with early amyloid beta (Aß) changes in the brain, while the CSF levels of p-tau205 are foremost related to tau pathology in the later stages of the disease. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed